Strand Therapeutics is developing programmable mRNA-based therapeutics that combine self-replicating and circular RNA modalities with genetically programmed logic circuits to enable precise, controlled payload delivery. Its platform is designed to localize and durably express therapeutic payloads, including IL-12, to reprogram the tumor microenvironment and stimulate systemic anti-tumor immunity. The lead program, STX-001, is a self-replicating mRNA encoding IL-12 that is in a Phase 1/2 clinical trial (IND cleared December 2023) and presented early human data at the 2025 ASCO Annual Meeting showing multiple RECIST responses, complete responses, prolonged disease stabilization, and a favorable safety profile. Strand also presented preclinical data for STX-003, a first-in-class systemically administrable, tumor-targeting mRNA therapy programmed to avoid off-target delivery including liver avoidance, at AACR and ASGCT. The company emphasizes a computational design engine and modular platform intended to expand into immuno-oncology, cell therapy, autoimmune diseases, and other indications, and to enable partnerships and licensing opportunities. Strand Therapeutics engineers programmable, long-acting mRNA therapeutics delivered in nanoparticles to control the location, timing, intensity, and duration of protein expression in patients. Its platform programs genetic logic circuits so mRNA senses microRNA signatures and restricts expression to target cells, aiming for improved efficacy and safety versus first-generation mRNA. The company is developing a pipeline of multifunctional mRNA candidates, including a lead programmable mRNA therapy for solid tumor immuno-oncology. Strand plans to advance that lead candidate into Phase 1 clinical trials next year and to further develop a systemic delivery mechanism to target tumor sites and immune cells. The company will expand its biology, bioengineering, bioinformatics, manufacturing, automation, and G&A teams to support clinical and delivery development. Strand is headquartered in Boston and has announced a Series A financing totaling $97 million to support these efforts. Strand Therapeutics develops programmable, long-acting self-replicating mRNA therapeutics designed to enable precise control of location, timing, intensity, and duration of therapeutic activity. Its platform combines self-replicating mRNAs with genetically programmed logic circuits that sense and classify cell-type expression signatures to deliver multi-functional treatments in a single mRNA drug. The company’s initial focus is cancer immunotherapy, with plans to begin clinical trials of its first candidate in 2022 and ambitions to address solid tumors and hematological malignancies. Strand is also developing programmable mRNA for generation of cell therapies intended to be re-doseable and off-the-shelf to expand patient access. The company has a licensing collaboration with BeiGene to develop and commercialize its multi-functional mRNA technology for solid tumor immuno-oncology. Financially, Strand announced an oversubscribed $52M Series A and has raised $66M in total to date. Strand Therapeutics is an early-stage biotechnology company building programmable, “smart” mRNA therapeutics using synthetic biology innovations developed at MIT. The company says it created a bespoke programming language to enable mRNA therapies that can make sophisticated decisions and dynamically respond to their microenvironment. Scientific co-founders include MIT professors Ron Weiss and Darrell J. Irvine; operational co-founders are Jacob Becraft (CEO) and Tasuku Kitada (President). Strand is initially targeting immuno-oncology and plans to extend into other disease indications as the platform matures. The company will use its latest financing to hire at its Cambridge, Massachusetts headquarters, grow its pipeline of engineered gene therapies, and further develop its synthetic biology platform. Strand is a resident company of Johnson & Johnson Innovation, JLABS.

Total raised

$256M

Funding rounds

4

Latest round

Series B

Latest activity

Aug 2025